5 Top NASDAQ Biotech Stocks: Neovasc Wins the Week
Neovasc, Arbutus Biopharma, Aralez Pharmaceuticals, CASI Pharmaceuticals and Nabriva Therapeutics top the NASDAQ biotech stock list.
Your trusted source for investing success
Your trusted source for investing success
Neovasc, Arbutus Biopharma, Aralez Pharmaceuticals, CASI Pharmaceuticals and Nabriva Therapeutics top the NASDAQ biotech stock list.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it has closed on its previously announced registered direct offering, priced at-the-market. Pursuant to securities purchase agreements entered into with certain institutional investors, DelMar sold an aggregate of 8,000,000 shares of common stock
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).
DelMar’s new patent strengthens the Company’s control over
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
Theralase Technologies shared new results from its patented and lead anti-cancer drug TLD-1433, in fighting a human pharyngeal carcinoma cell line.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.
“The opening of this
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
Major players in the pharmaceutical industry include Johnson & Johnson, Novartis, Roche, Pfizer and Merck.
Oncolytics Biotech announced the presentation of two posters on REOLYSIN at the European Society for Medical Oncology.
ESSA Pharma announced the results from its Phase 1 portion of the clinical trial of EPI-506 for the treatment of metastatic castration-resistant prostate cancer were presented at the European Society for Medical Oncology.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the initiation of a Phase 2 clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as
GT Biopharma announced the appointment of Dr. Raymond Urbanski as their new chief medical officer.
GT Biopharma announced today the closing of their merger with Georgetown Translational Pharmaceuticals.
Oncology investing can certainly be intimidating. Here, the Investing News Network looks at companies in the space and other ways to invest.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
The Investing News reported took a closer look at some of the big cannabis news of the week and published an interview with the president of Cannabis Wheaton.
INN talks with Dave Berg from Strainprint about the vital role of data collection in the medical cannabis market.
